Victor Ferreira, PhD
@victorhferreira.bsky.social
Assistant Scientist, UHN
Assistant Professor, University of Toronto (LMP & IMS)
Research Interests: systems vaccinology, viral immunology, elimination of latent/chronic viruses.
Assistant Professor, University of Toronto (LMP & IMS)
Research Interests: systems vaccinology, viral immunology, elimination of latent/chronic viruses.
Today is my 11th year anniversary at @uhnresearch.ca!
Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.
Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.
November 10, 2025 at 6:30 PM
Today is my 11th year anniversary at @uhnresearch.ca!
Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.
Very thankful for the amazing colleagues, trainees and friends I've made over the years and excited for the new connections and discoveries on the horizon.
Our first publication addressing RSV vaccination in transplant recipients is now available in Clinical Microbiology and Infection: www.sciencedirect.com/science/arti...
We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.
We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.
Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study
Allogeneic hematopoietic cell transplant (alloHCT) and lung transplant (LT) recipients are at highest risk for severe respiratory syncytial virus (RSV…
www.sciencedirect.com
September 29, 2025 at 4:27 PM
Our first publication addressing RSV vaccination in transplant recipients is now available in Clinical Microbiology and Infection: www.sciencedirect.com/science/arti...
We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.
We found marginal rates of seroconversion but robust CD4+ T cell responses after a single dose of adjuvanted vaccine.
Our latest work 🚨 a first-in-human study:
We show that rituximab delivery via ex vivo lung perfusion is feasible and safe.
With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation.
journals.lww.com/transplantat...
We show that rituximab delivery via ex vivo lung perfusion is feasible and safe.
With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation.
journals.lww.com/transplantat...
Feasibility and Safety of Ex Vivo Delivery of Rituximab to... : Transplantation Direct
virus (EBV)-seropositive donors for transplantation into EBV-seronegative recipients (D+/R–) to reduce the risk of EBV-associated posttransplant lymphoproliferative disorder (PTLD), which remains a ma...
journals.lww.com
March 28, 2025 at 5:00 PM
Our latest work 🚨 a first-in-human study:
We show that rituximab delivery via ex vivo lung perfusion is feasible and safe.
With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation.
journals.lww.com/transplantat...
We show that rituximab delivery via ex vivo lung perfusion is feasible and safe.
With some modifications, this could become a new way to eliminate EBV in donor lungs prior to transplantation.
journals.lww.com/transplantat...
Reposted by Victor Ferreira, PhD
UHN, Canada’s top hospital, is ranked third in the world for the second year in a row by @newsweek.com! This 2025 ranking solidifies UHN’s Toronto General Hospital as the top publicly-funded hospital in the world.
Read the full report here:
www.newsweek.com/rankings/wor...
Read the full report here:
www.newsweek.com/rankings/wor...
February 26, 2025 at 2:42 PM
UHN, Canada’s top hospital, is ranked third in the world for the second year in a row by @newsweek.com! This 2025 ranking solidifies UHN’s Toronto General Hospital as the top publicly-funded hospital in the world.
Read the full report here:
www.newsweek.com/rankings/wor...
Read the full report here:
www.newsweek.com/rankings/wor...
Reposted by Victor Ferreira, PhD
In Press and Open Access! "Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients" by Azarfar et al. https://buff.ly/43u19aH
@victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination
@victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination
February 24, 2025 at 9:15 PM
In Press and Open Access! "Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients" by Azarfar et al. https://buff.ly/43u19aH
@victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination
@victorhferreira.bsky.social #MachineLearning #SolidOrganTransplantation #Vaccination
Can anyone shed light on the new CIHR rankings? Is it safe to assume that all projects that rank in top 10% will be funded? Do we expect that some applications in the 11-25% rank will also be funded?
January 15, 2025 at 4:43 PM
Can anyone shed light on the new CIHR rankings? Is it safe to assume that all projects that rank in top 10% will be funded? Do we expect that some applications in the 11-25% rank will also be funded?
Reposted by Victor Ferreira, PhD
While immunocompromised individuals had a heterogeneous antibody response to RSV vaccines, those who received the adjuvanted RSVPreF3-AS01 vaccine showed better neutralization.
ja.ma/4iVzJzy
ja.ma/4iVzJzy
December 30, 2024 at 6:25 PM
While immunocompromised individuals had a heterogeneous antibody response to RSV vaccines, those who received the adjuvanted RSVPreF3-AS01 vaccine showed better neutralization.
ja.ma/4iVzJzy
ja.ma/4iVzJzy
Reposted by Victor Ferreira, PhD
Excellent study by my Penn-CEIRR colleagues showing that a single HA substitution in H5 (at same exact residue that changed in the British Columbia case!) enables efficient H5N1 binding to receptors in the human upper airway.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors
In 2024, several human infections with highly pathogenic clade 2.3.4.4b bovine influenza H5N1 viruses in the United States raised concerns about their capability for bovine-to-human or even human-to-h...
www.science.org
December 5, 2024 at 7:49 PM
Excellent study by my Penn-CEIRR colleagues showing that a single HA substitution in H5 (at same exact residue that changed in the British Columbia case!) enables efficient H5N1 binding to receptors in the human upper airway.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Can machine learning be used to predict SARS-CoV-2 vaccine responses in immunocompromised transplant recipients one year after their first dose of vaccine?
Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.
Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.
Using Machine Learning for Personalized Prediction of Longitudinal COVID-19 Vaccine Responses in Transplant Recipients
The COVID-19 pandemic has underscored the importance of vaccines, especially for immunocompromised populations like solid organ transplant (SOT) recip…
tinyurl.com
December 5, 2024 at 6:09 PM
Can machine learning be used to predict SARS-CoV-2 vaccine responses in immunocompromised transplant recipients one year after their first dose of vaccine?
Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.
Our latest study, accepted at American Journal of Transplantation, explores this question: tinyurl.com/59ehzfmk.
Pleased to share that our project (led by Victoria Hall, Atul Humar, Deepali Kumar, and myself) was one of 35 selected for funding to address the risk of avian influenza in Canada. We will study H5 vaccine responses & safety in immunocompromised transplant recipients.
www.canada.ca/en/institute...
www.canada.ca/en/institute...
Government of Canada invests in research on avian influenza A(H5N1) - Canada.ca
Avian influenza A(H5N1), commonly known as bird flu, is a viral disease that is typically transmitted between wild birds and poultry but can spread to other birds and mammals. Based on current evidenc...
www.canada.ca
November 26, 2024 at 8:03 PM
Pleased to share that our project (led by Victoria Hall, Atul Humar, Deepali Kumar, and myself) was one of 35 selected for funding to address the risk of avian influenza in Canada. We will study H5 vaccine responses & safety in immunocompromised transplant recipients.
www.canada.ca/en/institute...
www.canada.ca/en/institute...